iBio, Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the quarterly period ended September 30, 2026, reporting a net loss of $7,551 thousand and total assets of $88,651 thousand.

Key Highlights

  • Net loss of $7,551 thousand for the three months ended September 30, 2026, compared to a net loss of $5,720 thousand for the same period in 2025, according to the filing.
  • Revenue of $1,075 thousand for the three months ended September 30, 2026, up from $100 thousand in the prior-year quarter, as reported in the filing.
  • Cash and cash equivalents of $45,435 thousand as of September 30, 2026, compared to $56,395 thousand as of June 30, 2026.
  • Total assets of $88,651 thousand as of September 30, 2026, down from $99,110 thousand as of June 30, 2026.
  • Common shares outstanding of 64,307,256 as of September 30, 2026, increased from 55,698,561 as of June 30, 2026, reflecting exercise of warrants and pre-funded warrants.
  • Accumulated deficit of $372,819 thousand as of September 30, 2026, per the condensed consolidated balance sheet.
  • Total stockholders' equity of $78,570 thousand as of September 30, 2026, compared to $85,713 thousand as of June 30, 2026.

iBio's First Fiscal Quarter 2027 Financial Results: Revenue Growth, Wider Net Loss

According to the Form 10-Q filed by iBio, Inc. (NASDAQ:IBIO) for the quarterly period ended September 30, 2026, the company reported revenue of $1,075 thousand, a significant increase from $100 thousand in the three months ended September 30, 2025. Total operating expenses rose to $9,413 thousand from $6,051 thousand in the prior-year quarter, with research and development expenses increasing to $6,650 thousand from $3,550 thousand and general and administrative expenses rising to $2,763 thousand from $2,501 thousand. The resulting operating loss was $8,338 thousand, compared to an operating loss of $5,951 thousand in the prior-year period.

The filing disclosed interest income of $787 thousand for the quarter, up from $265 thousand in the same period of the prior year, partially offsetting the operating loss. After accounting for other income, the net loss before income taxes was $7,551 thousand, with no income tax expense recorded. The loss per common share on a basic and diluted basis was $(0.05), compared to $(0.11) for the three months ended September 30, 2025. The weighted-average common shares outstanding on a basic and diluted basis were reported as 151,574 thousand for the current quarter and 52,981 thousand for the prior-year quarter.

On the balance sheet, the company disclosed investments in debt securities with a carrying value of $31,219 thousand as of September 30, 2026, against an adjusted cost of $31,342 thousand. Intangible assets, net of accumulated amortization, increased to $2,570 thousand from $1,825 thousand at June 30, 2026. During the quarter, the company recorded share-based compensation of $435 thousand, and the exercise of pre-funded warrants added 8,544 thousand shares. As of November 10, 2026, shares of common stock outstanding were reported as 70,455,809.

What Was Disclosed

iBio, Inc. disclosed its unaudited condensed consolidated financial results for the three months ended September 30, 2026, including a net loss of $7,551 thousand, revenue of $1,075 thousand, total assets of $88,651 thousand, and an accumulated deficit of $372,819 thousand, in a Form 10-Q filed November 10, 2026.